110 – Adverse Event Reporting Explained (S8E5)

You know, when we think about all the medicines
and medical devices out there, like the ones
we all rely on, well, keeping them safe, that's
a big deal, right? Huge. It really is. And for
folks who want to know how that safety net actually
works, today we're taking a deep dive into adverse
event reporting. Yeah. Fascinating stuff. We're
going to sort of like peel back the layers and
see how potential issues with these medical products
are first spotted, how that information gets
to the right people, and then how it's all analyzed
to keep us all safe. It's a whole system. It
is. And you know, our sources for this deep dive
give us this amazing look at the whole picture
from the very beginning when a drug is being
developed all the way to what happens when it's
out there being used by lots of people. We'll
look at the regulations, the steps involved in
reporting these events and all the work that's
being done to constantly improve the system.
So where do we even start? Like how is a potential
adverse event even first noticed? Well, it's
really monitored all the time throughout the
whole life cycle of a drug or a medical device.
Before a treatment is ever given to a person,
there's already a bunch of checks in place. Like
our sources point out, preclinical toxicology
studies, they're crucial for spotting any early
warning signs. And animals, of course. So this
isn't just like a quick glance, right? These
are pretty in -depth studies. Oh yeah, incredibly
thorough. Scientists look at a whole bunch of
things. I mean, some are obvious, like do the
animals, you know, die more often. But they also
look for subtle signs of illness. And they're
very careful about tracking changes in things
like body weight, how much food they eat, and
then they go deep, like blood work, you know,
hematology, looking at their urine, even examining
the animal's organs. That's the gross pathology.
And then even zooming in further by studying
tissue samples under a microscope, histopathology.
It's all to get a really complete picture of
potential problems way before any human trials
begin. Right, because you don't want to find
that out later on. Exactly. and catching those
early signs, even in animals. Because, of course,
it's not a perfect prediction of how humans will
react. But it really helps to reduce the chance
of big problems later down the line. It's like
testing the waters, like you said. Yeah. So then
we move on to clinical trials, where they're
actually using the treatment in people. How do
they keep track of adverse events in those trials?
Well, in clinical trials, especially in what
are called phase three trials, which are also
looking at drugs that are meant to be used for
a long time, the people in those trials They're
given the drug for longer periods, and that's
deliberate. It's to collect more data on safety.
Because the longer someone's taking a drug, the
more chance there is of spotting those less common
or delayed side effects that might not show up
in shorter studies. So they're not just seeing
if the drug works. They're watching very closely
to see if it causes any harm. Absolutely. Safety
is a top, top priority throughout the entire
drug development process. And it's important
to remember that this monitoring, it doesn't
just stop when a drug gets approved and is available
to everyone. Actually, post -market surveillance,
that's what it's called. It's a really crucial
phase for identifying adverse events, because
now you've got a much bigger and more diverse
group of people taking the drug that you could
ever have in a clinical trial. Right. Right.
Out in the real world. Makes sense. Yeah. OK.
We know adverse events are always being watched
for, but what happens when somebody like a doctor
or a patient actually thinks they see one? How
do they report it? Like, what's the actual process?
That's where all these reporting processes come
in. Regulatory bodies, you know, the ones in
charge of making sure things are done properly,
they've set up systems for this very reason.
In the U .S., the big one is the FDA, the Food
and Drug Administration, and they have a system
called FEAR -EARS, the FDA Adverse Event Reporting
System. It's basically a central database where
all these reports from healthcare professionals,
patients, even the drug manufacturers, they all
go there. F -airs. Okay, I'll try to remember
that one. It is kind of a mouthful. But who does
the reporting? Like, who's actually sending these
reports in? Oh, it's a joint effort, really.
So you've got healthcare professionals like doctors,
nurses, pharmacists. They're all supposed to
report any suspected adverse events they see
in their patients. But what's interesting is
patients can report things directly to. To the
agencies or to the company that makes the drug.
So if I think I'm having a bad reaction to something.
You can report it. Interesting. And then of course
the manufacturers themselves. They're required
by law to have their own systems to receive investigate
and then report any adverse events They hear
about if they're related to their products. So
they're listening. They're monitoring Oh, absolutely.
Yeah, and our sources make it clear that they
aren't just sitting around waiting for reports
They have to be proactive like if they spot something
unusual in their own quality control checks or
during manufacturing Anything that raises concerns
about the safety of their products. They have
to investigate it It makes sense. It's a big
responsibility. Which, speaking of, let's talk
about the regulations. Like, what are some of
the key requirements and responsibilities that
the drug companies have when it comes to all
this? Well, they've got to comply with a whole
bunch of regulations. And our sources point out
that this covers everything from the moment they
get those raw materials to make the drug, all
the way to when the finished product is shipped
out. Yeah. Every step. And one really big part
of this is keeping very detailed records. An
audit trail, basically. Exactly like for every
single batch of an intermediate product or the
final active pharmaceutical ingredient API is
what they call it It has to be reviewed and approved
by quality control before they can move on to
the next step You know whether it's making more
of it or sending it out and there's this other
requirement where they have to review everything
once a year Wow, that's a lot. Yeah all the batch
production records the stability data that shows
how well the product holds up over time and any
complaints they've gotten. This big annual check
is to make sure that all their controls during
the process, the ways they make it, the specs
of the final product, that's all still good,
or if they need to change things. It's like a
constant process of checking and rechecking.
Yeah, it really is. OK, so what happens if they
find out something new about a drug's safety,
like after it's been approved and people are
already taking it? How do they handle that new
information? That's where they have these things
called risk evaluation and mitigation strategies,
or REMS. Our sources don't go into a ton of detail,
but it's really important to understand. The
FDA can require a company to have a REMS, to
make sure that a medicine's benefits still outweigh
the risks, especially if new safety issues come
up after it's already being used. There's all
sorts of things they can do, like maybe doctors
have to follow special rules when prescribing
it, or maybe patients have to go through a certain
educational program to learn about the risks,
or maybe patients taking the drug have to be
monitored really closely. So it's not just about,
like, pulling the drug off the market? No, no.
It's more about managing the risk proactively.
It's a balancing act, right? Making sure people
can still access treatments they need, but doing
it safely. Makes sense. Yeah. OK. So we've talked
about identifying and reporting adverse events
and the whole regulatory side of things. But
what happens to all that data that gets sent
in? How do they go through it to figure out if
there are any safety problems? Well, that's where
adverse event analysis and signal detection come
in. They get so many reports, so they have to
go through it all and try to spot potential safety
signals. A safety signal is like an early warning,
it might mean there's a new risk associated with
a medicine or a device. So they're looking for
a needle in a haystack, basically. It really
is a lot of data, and there's a few reasons why
signal detection is so tricky. For one, sometimes
it's hard to tell the difference between a side
effect from a drug and just you know, someone
getting sick from something else, because people
get sick all the time, so you have to see if
something's happening more often in people taking
a certain drug than you'd expect normally. And
then you have the issue of, you know, people
often take lots of different medications at the
same time. That's polypharmacy, and it makes
it hard to know which drug might be causing a
problem. So it's not always simple to connect
the dots. No. Not at all. That's why they use
all these statistical methods to analyze all
that data, to look for unusual patterns. And
then the regulatory agencies, like the FDA, they
use this information to figure out what to do
next. Maybe they'll ask the company to update
the drug label with new warnings. Or, in really
serious cases, they might even think about pulling
the drug from the market if they think it's too
risky. So the analysis guides the action. Yeah.
Think of it like this. If you're looking at a
bunch of data about daily temperatures and you
see a sudden spike, it doesn't necessarily mean
there's a heat wave coming, but it's something
you'd want to look into. I like that analogy.
It's all about patterns. Now, our sources don't
give us specific examples of like really big
adverse events and what happened afterwards,
but can we talk generally about like What kind
of impact it has when serious safety issues are
found? Sure. When there's a serious adverse event
that everyone agrees is definitely a problem,
it can have a big ripple effect. Often, health
care professionals get new guidelines for prescribing
the drug so they might start using it more cautiously
or only in certain situations. Sometimes the
regulatory agencies make the company add what
they call a black box warning to the drugs label.
That's like the most serious type of warning.
It highlights risks that could be life -threatening.
And obviously stuff like this leads to more scrutiny,
not just of that particular drug, but sometimes
of other similar drugs, too. So it can shake
things up. Yeah, it does. And beyond just the
immediate response, you know, from doctors and
regulators, what about public perception? Does
it affect how people view the drug companies
and the agencies that are supposed to be keeping
things safe? Events like these, where a drug
turns out to be more risky than people thought,
can definitely erode public trust. Both in the
pharmaceutical industry, making the drugs, and
the agencies in charge of safety. It's really
important for everyone to be open about the risks
and to communicate clearly about what's happening.
That's how you maintain trust and make sure both
health care providers and patients are informed.
Transparency is key. Absolutely. OK, now one
of the biggest challenges in all of this is underreporting.
Like we know adverse events don't always get
reported. Why is that? And what are the implications?
Underreporting is a big issue. A lot of reasons
why it happens. Sometimes patients or even health
care professionals don't realize that a symptom
could be related to a medicine or they might
not think it's a big deal and not bother reporting
it. And sometimes the process itself can feel
like a hassle, too complicated or time -consuming.
And then, like we were talking about earlier,
it's not always clear if something was actually
caused by the drug or by something else entirely.
So it's a mix of things. Awareness, how easy
the reporting process is, and just the basic
difficulty of figuring out cause and effect.
Makes sense. But what does this underreporting
mean in the big picture? Well, it means we might
not be getting the full story about a drug's
safety. If only a small percentage of adverse
events are actually reported, it can take a lot
longer to spot important safety signals. And
that could mean more people are at risk before
the problem is fully understood and addressed.
It's a real concern. It is. So given all these
challenges, what's being done to improve things?
What's on the horizon for adverse event reporting
and pharmacovigilance? Well, there's a lot happening,
actually. Lots of innovation. New data mining
techniques are letting them analyze those huge
amounts of data in more sophisticated ways. And
electronic health records, those are becoming
more and more common, and they have the potential
to make it much easier to capture and share safety
information. And they're working on ways to make
reporting easier for everyone, like user -friendly
online portals, integrating it into the systems
that doctors and hospitals are already using.
And global collaboration is becoming more and
more important, because sharing safety information
between countries gives you a more complete picture
of a drug's safety around the world. So technology
and better communication are playing a big role.
Absolutely. Huge. Being able to collect, share,
and analyze all that data efficiently, that's
what's going to make a big difference. This has
been a really fascinating deep dive. We've covered
a lot. How adverse events are first spotted,
the systems for reporting them, the regulations,
how they analyze all that data to look for safety
signals. We even touched on the impact of all
this, the challenges with under -reporting, and
what the future holds for this whole field. It's
so important for protecting public health. It
really is. When you understand how all these
systems work, you really get a sense of just
how much effort goes into making sure medicines
and medical devices are used safely. It's pretty
impressive. And after learning all about the
complexities of adverse event reporting and all
the work that goes into keeping us safe, it really
makes you wonder, what else can we do to make
things even better? What other innovations are
out there that could really change the game when
it comes to monitoring the safety of medicines
and keeping people healthy? Something to think
about. Anyway, thanks for joining us for this
deep dive. It's been a pleasure. Thanks for having
me.